Objective:To investigate the antihypertensive efficacy of
arotinolol(Almarl)and its influence on sleep breathing. Method:Twenty
essencial hypertension patients were treated by a random,single blind and self controled study and observed by polysomnography,ambulatory blood pressure monitoring. Results:After four weeks drug administration,systolic blood pressure was reduced from 21.7±2.0 kPa(163±15 mmHg)to 18.9±2.5 kPa(142±19 mmHg)( p =0.000, n =20),diastolic blood pressure was reduced from 13.5±0.9 kPa(101±7 mmHg)to 11.7±0.9 kPa(88±7 mmHg)( p =0.000, n =20).Five patients with obstructive sleep apnea showed a decrease of apnea hypopnea indices(AHI) from 24.60 to 13.16( p <0.05, n =5).Ultrasonic cardiography indicated significant improvements in cardiac function.The heart rates were not
significantly decreased.After treatment the serum high density lipoprotein cholesterol (HDL C)increased and the renin concentration decreased. Conclusion:Arotinolol can reduce both of the systolic blood pressure and diastolic blood pressure of the patients significantly,and it also improve the sleep
breathing disorder in the patients with obstructive sleep apnea.After the treatment,the serum HDL c were increased and the renin concentration decreased.It did not significantly affect the heart rate of all patients.